You are here

Article info

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta analysis
Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes

Authors

  • Rene Rodriguez-Gutierrez Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA Division of Endocrinology, University Hospital ‘Dr. Jose E. Gonzalez’ Autonomous University of Nuevo Leon, Monterrey, Mexico PubMed articlesGoogle scholar articles
  • Victor M Montori Knowledge and Evaluation Research Unit and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Victor M Montori, Knowledge and Evaluation Research Unit and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; montori.victor{at}mayo.edu
View Full Text

Citation

Rodriguez-Gutierrez R, Montori VM
Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes
BMJ Evidence-Based Medicine 2016;21:224.

Publication history

  • First published October 18, 2016.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/